ERBB2 and breast carcinoma: Our data confirm that the presence of PIK3CA mutations is associated with reduced sensitivity to both trastuzumab monotherapy and the dual anti-HER2 blockade with trastuzumab plus pertuzumab in HER2+ breast cancer preclinical models.